Novel Drug Regimen for the Treatment of Alzheimer's Disease


Executive Summary


Alzheimers’ disease (AD), the leading cause of dementia is a very complex disorder with a variety of molecular and cellular pathological alterations. For many patients, the current pharmacological treatment proves ineffective. Current research suggests that changes in the polyamine levels are a possible factor in causing Alzheimer’s disease and other mental and neurodegenerative disorders. MSU researchers are proposing a novel drug regimen for the treatment of AD based on an approved cancer pharmaceutical that affects the polyamine system, possibly alleviating and slowing down the progression of AD.


Description of Technology


The intake of an already established pharmaceutical for cancer treatment is suggested to be used alone or synergistically in combination with Vitamin E.  MSU researchers have identified that this drug irreversibly inhibits the activity of an enzyme in the polyamine pathway which may be linked to the onset and progression of AD.


Key Benefits

  • Good compliance of drug
  • Low cytotoxicity and low side effects of drug
  • Good blood-brain barrier permeability of drug



  • Treatment of Alzheimer’s disease and other neurodegenerative disorders


Patent Status: 


Under review


Licensing Rights Available


Full licensing rights available


Inventors: Andre Bachmann


Tech ID: TEC2016-0079


Alternative contact due to temporary leave:


Nina (Isi) Davis, Technology Marketing Manager, email:, phone (direct): (517)884-1829. 


Patent Information:


For Information, Contact:

Anupam Jhingran
Technology Manager
Michigan State University
Andre Bachmann